IN T R O D U C T IO N
T um our necrosis factor (TN F) is a cytokine produced by activated monocytes, m acrophages (Old 1985) and T-lym phocytes (Dett et al. 1990) . T N F causes haem orrhagic necrosis of certain transplantable tum ours in mice (Carswell et al. 1975) and is also involved in a spectrum of im portant immunological and inflam m atory reactions (Goeddel et al. 1986; Beutler & Cerami 1988) . Although the m olecular mechanisms whereby T N F induces these diverse responses is still unknown, it is necessary that T N F first bind to specific cell m em brane receptors (Bajzer et al. 1989; W atanabe et al. 1989) .
Two cell m em brane T N F receptors have been recently isolated, cloned and sequenced; one is 55 kDa Schall et al. 1990 ), the other is 75 kDa (Smith et al. 1990) . These T N F receptors both have an N -term inal extracellular dom ain (55 kDa: positions 39 to 212, 75 kD a: positions 23 to 257) with some amino acid (AA) homology, a short trans m em brane region and non-related C -term inal in tra cellular domains. Espevik et al. have shown that f To whom correspondence should be sent.
binding of m onoclonal antibodies to the 55 kDa receptor can mimic biological activities of T N F vitro, including cell cytotoxicity, stim ulation of fibroblast growth and interleukin 6 secretion by endothelial cells Espevik et al. 1990) . In contrast, m onoclonal antibodies against the 75 kDa receptor did not exhibit biological activity (Espevik et al. 1990) . Although it is possible that the 55 kDa receptor is physiologically more im portant, it is also possible that only the monoclonal antibody against the 55 kDa receptor binds to the active sites while the one against the 75 kDa receptor does not. 
M A T E R IA L S AND M E T H O D S (a) L929 cytolytic assay
Inhibition of cytolytic activity of recombinant human TNF against L929 mouse fibroblast cells was assayed by the method of Gatanaga et al. (1985) . Briefly, synthetic peptides (80 pg per well) and human TNF-a (Genentech Corpor ation, California) were pre-incubated at 37 °C for 1 h. They were then added to L929 cells (8 x 104 cells per well) and actinomycin D (0.2 pg per well) in 96 well Corning flatbottomed microcytotoxicity plates in 200 pi per well RPM I-1640 with 10% foetal calf serum (FCS). The control group was treated with the same volume of phosphate buffered saline (PBS) pH 7.2 instead of synthetic peptides. After incubation for 18 h at 37 °C, the supernatants were aspirated and the adherent viable cells stained with 1 % crystal violet for 5 min at room temperature. Excess dye was removed by rinsing with water, the plate was allowed to dry and cells were solubilized with 100 pi acidified methanol (100 iumHCI in methanol). Absorbance of each well was measured at 600 nm in an ea r 400 a t microplate reader (SLT-LabInstruments, Austria).
(b) TNF binding assay
O ne million L929 m onolayer cells were first incu bated with binding buffer (R P M I-1640 with 10% FCS) and peptides or antibodies in 24-well flatbottom ed Gibcoware culture plates for 1 h. They were then incubated with 0.5-15 ng of 125I-labelled hum an recom binant T N F (Amersham, il , specific activity 400 Ci mmol-1) in the presence or absence of a 100-fold excess of unlabelled hum an T N F (Cetus Corporation, California). After a 3-4 h incubation at 4 °C, binding buffer was removed and the cells were washed two to four times with ice-cold PBS. Cells were solubilized in 1 ml of 0.3 n N aO H and radioactivity was determ ined in a Pharm acia C linigam m a counter (Uppsala, Sweden).
(c) Synthetic peptides
Peptides were made on a Milligen 9050 peptide synthesizer (Milligen Biosearch, Bedford, Massachusetts) using Fmoc chemistry. Twenty percent piperidine in DMF was used to remove protecting groups. Cleavage and deprotection were done by 'Reagent R ' (Milligen Biosearch). Peptides were extracted with diethyl ether five separate times. The crude peptides made were purified by passage through a Vydac C4 reverse phase column in Waters 6000A high-performance liquid chromatography system (Waters Associates, Milford, Massachusetts).
(d) Antibody production
Peptides were conjugated with keyhole limpet haemocyanin (Sigma, Missouri) by the method of Fisher et al. (1989) and 200 pg of protein was injected into rabbits with Freund's complete or incomplete adjuvant each time by the method of Yamamoto et al. (1978) . After six injections, the antisera in different dilutions were used in TNF cytolytic and binding assays. Control sera were obtained from nonimmunized rabbits.
R E SU L T S
We (Schall et al. 1990 ) and others ) recently reported the complete amino acid sequence of the hum an 55 kDa cell m em brane TN F receptor. Shortly thereafter the complete AA sequence of the 75 kDa hum an T N F receptor was also reported (Smith et al. 1990) .
Sequence analysis and comparison of the 55 kDa and 75 kDa receptor with the Eugene com puter program shows four regions (Domain I-IV ) of at least 40% homology in the N -term inal extracellular region ( figure 1 a) . Dom ain IV is the proposed transm em brane dom ain. Two 20 AA synthetic peptides were synthe sized representing sequences 75 to 94 (peptide A) and 175 to 194 (peptide B) of the 55 kDa receptor ( figure  1 b) . Peptide A shares 17 amino acids with Domain I of the 55 kDa receptor and 7 with that of the 75 kDa receptor. The homology between peptide A and the corresponding region of the 75 kDa receptor is approxi mately 40% . Peptide B is identical to a stretch of sequence between Dom ain III and Dom ain IV in the 55 kDa receptor. No homology was evident between peptide B and any region of the 75 kDa receptor. T he results shown in figure 2 reveal th at peptide B significantly blocked T N F activity while peptide A showed no blocking activity. T he effect of these peptides on 125I-labelled T N F binding assay was also examined.
Synthetic peptide blocking T N F a c t i v i t y C. Hwang and others
The results in figure 3 show that peptide B at the level tested blocked about 50% of T N F binding to the T N F receptor of L929 cells. In contrast, peptide A had no effect on T N F binding in this system. In addition, we found that synthetic peptides with AA sequences unrelated to AA sequences in the 55 kDa receptor had no blocking activity (data not shown).
R abbits were immunized with both peptides as described in M aterials and methods. Antisera from animals immunized with peptide B showed blocking activity in the T N F cytolytic assay (data not shown). The d ata suggested that anti-peptide antibodies bound T he effect of these antisera on the 125I-labelled T N F binding assay was examined. The d ata in figure 4 show that the serum from animals im m unized against peptide B blocked 71% of T N F binding com pared with control serum.
DISCUSSION
It is not clear which regions on the T N F molecule and their corresponding cell surface receptor(s) inter act. However, binding of T N F with its specific cell surface receptor is the necessary first step in inducing subsequent effects (Bajzer et al. 1989; W atanabe et al. 1989) . T he ultrastructure of T N F has been elucidated down to 2.6 Af (Eck & Sprang 1989) . T he putative receptor binding site on TN F, proposed by these authors, was a concave surface. They suggested that the binding site of the m em brane receptor for T N F should be an extended structure on a hydrophilic dom ain.
Synthetic peptides have been very im portant in elucidating structure-function relation studies. Baird et al. (1987) used a series of synthetic peptides to identify two functional domains in basic hum an fibroblast growth factor (FGF) that can bind both heparin and the hum an FGF receptor. Antibodies to synthetic peptides have also been used to identify specific regions on proteins involved in functional activity in hum an in terleu k in -1 (Boraschi & T agliabue 1989) We produced 20 AA synthetic peptides identical to two hydrophilic regions of the N -term inal extracellular f 1 angstrom -1CT10 m = 10_1 nm.
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dom ain of the hum an 55 kDa TN F receptor. We assumed that these hydrophilic regions are exposed portions of the TN F receptor and thus accessible to and perhaps involved in TN F binding. The data we presented suggest that peptide B is probably within or near the binding dom ain of the hum an 55 kDa TN F receptor.
Both 55 kDa and 75 kDa TN F hum an receptors belong to a family of m em brane proteins having cysteine-rich regions Schall et al. 1990; Smith et al. 1990 ). In our previous report, com puter analysis revealed that the 55 kDa TN F receptor has four internal cysteine repeats (Schall et al. 1990) . Further analysis revealed that homologous domains between 55 kDa and 75 kDa T N F receptors are located at the junctions of these internal cysteine repeats. Peptide A represents a 20 AA sequence from the first homologous dom ain and is located at the junction between the first and second internal cysteine repeats. Peptide B represents 20 AA residues found in the central portion of the fourth internal cysteine repeat. The finding that peptide B is im portant for binding supports the idea that these internal cysteine repeats may be im portant to form the stereochemical structures necessary for receptor functions. The central portions of these internal cysteine repeats may be a good target area for further structure-function studies.
It is im portant to point out that our antisera were made against hum an 55 kDa T N F receptors and we dem onstrated they could bind to m urine T N F recep tors on L929 cells. These results suggest that this region in the 55 kDa T N F receptor has been conserved in evolutionary development. This is logical because hum an T N F can cross species and bind to and kill susceptible cells from various anim al species. The data presented here suggest that AA residues from 174 to 195 in the amino term inal extracellular dom ain of the 55 kDa T N F receptor are involved in the actual site for T N F binding.
